Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02220842 · ClinicalTrials.gov registry record · Phase 1
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
A Phase 1 study of Lymphoma, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 15
- Study locations
NCT02220842: Completed Phase 1 study of Lymphoma, sponsored by Hoffmann-La Roche.
NCT02220842 is a Phase 1 study of Lymphoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 96 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (80% lower). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02220842, a Phase 1 study of Lymphoma, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 15
- Study locations
Study Summary
This open-label, multicenter, global study is designed to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of intravenous atezolizumab (MPDL3280A) and obinutuzumab in participants with refractory or relapsed follicular lymphoma (FL) or atezolizumab and obinutuzumab or tazemetostat administered in participants with refractory or relapsed diffuse large B-cell lymphoma (DLBCL). The anticipated duration of this study is approximately 4.5 years.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Atezolizumab
- DRUG Tazemetostat
Study Locations (15)
Other
- Hopital Claude Huriez - CHU Lille; Service des maladies du sang - Lille
- Hopital Saint Eloi - Montpellier
- Hôpital Saint-Louis - Paris
- Centre Hospitalier Lyon Sud - Pierre-Bénite
- Institut Gustave Roussy - Villejuif
- Universitaetsklinikum Freiburg - Freiburg im Breisgau
- Barts Hospital - London
California
- City of Hope National Medical Center - Duarte
Indiana
- Fort Wayne Neurological Center - Fort Wayne
New Jersey
- Hackensack University Medical Center - Hackensack
New York
- Sloan Kettering Cancer Center - New York
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Texas
- MD Anderson Cancer Center - Houston
Washington
- UW- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2014-12-18 |
| Est. Completion | 2020-01-21 |
| Phase | Phase 1 |
What the finished NCT02220842 record still lists
NCT02220842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT02220842 lists 15 locations in 9 states (Other, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT02220842 about?
NCT02220842 is a clinical study titled "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma". This open-label, multicenter, global study is designed to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of intravenous atezolizumab (MPDL3280A) and obinutuzumab in participants with refractory or relapsed follicular lymphoma (FL) or atezolizumab and obinutuzumab or taze...
What is the current status of trial NCT02220842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2014-12-18. Estimated completion is 2020-01-21.
What conditions does trial NCT02220842 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT02220842?
The interventions under investigation include: Obinutuzumab (DRUG), Atezolizumab (DRUG), Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT02220842?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02220842 being conducted?
This trial has 15 study locations across California, Indiana, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02220842's enrollment target sits among peer trials
96 90th of 299 higher than 210 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI